Andrea Lobo

Porto

Scientific Writer at Freelance

Articles

Study reinforces inflammation's role in Parkinson's development

5 days ago | parkinsonsnewstoday.com | Andrea Lobo

Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently published data showing IC 100, its experimental therapy for Parkinson’s, prevented the activation of inflammatory pathways in microglia.
Apathy treatment IRL757 found safe in multiple doses

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending doses of the Irlab Therapeutics treatment in healthy volunteers.
Givlaari safe, effective for acute hepatic porphyria patients: Study

1 week ago | porphyrianews.com | Andrea Lobo

Givlaari (givosiran) safely led to reductions in porphyria attacks and improved the quality of life of people with acute hepatic porphyria (AHP) in Japan in an expanded access program, according to newly shared results. The researchers noted that earlier trial data had “indicated that [Givlaari] may be an important treatment option for patients with AHP” — findings that the team suggested are substantiated by these results.
High mortality from pneumococcal meningitis in children with SCD

1 week ago | sicklecellanemianews.com | Andrea Lobo

Meningitis — an inflammation of the protective membranes surrounding the brain and spinal cord — remains associated with a case-fatality rate of nearly 30% in children with sickle cell disease (SCD), according to the findings of a new two-decade study from France. This is despite vaccinations for SCD children against the pneumococcal bacteria that cause meningitis and other diseases.
Good safety seen with FA drug Skyclarys over 1 year in real world

1 week ago | friedreichsataxianews.com | Andrea Lobo

The approved Friedreich’s ataxia (FA) drug Skyclarys (omaveloxolone) was found to be generally safe and well tolerated in people with FA in the real world, according to a new U.S. study that tested the medication’s safety over one year. Most patients remained on Skyclarys for more than 12 months after starting treatment, and the side effects seen were “modest” and manageable, per the researchers.
$5M grant to support research into cystic fibrosis lung transplant complications

1 week ago | cysticfibrosisnewstoday.com | Andrea Lobo

The Cystic Fibrosis Foundation (CFF) has awarded $5 million to the Cleveland Clinic to continue as the biorepository coordinating center for the Cystic Fibrosis Lung Transplant Consortium until 2030, supporting research and other efforts to improve lung transplant outcomes.
Walk in New York opens to aid access to advanced mobility devices...

1 week ago | multiplesclerosisnewstoday.com | Andrea Lobo

Wandercraft has launched Walk in New York, a new rehabilitation center that offers access to its advanced mobility devices for people with severe walking impairments, including those with multiple sclerosis (MS). The center provides sessions with neurological rehabilitation therapists and walking sessions with its robotic exoskeleton, Atalante X, along with other therapeutic tools.
Adrenal Cushing's patients in Japan show fewer syndrome features

2 weeks ago | cushingsdiseasenews.com | Andrea Lobo

People with adrenal Cushing’s syndrome who were diagnosed in the 2000s often had the condition identified incidentally — but also experience fewer symptoms specific to Cushing’s compared with individuals receiving a diagnosis in previous decades, a study in Japan has found. However, the prevalence of Cushing’s-related complications, including cardiovascular events and severe infections, remains elevated, data show.
Montara gets grant to develop LRRK2 inhibitor drug for Parkinson's

2 weeks ago | parkinsonsnewstoday.com | Andrea Lobo

The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop a brain-selective therapy for Parkinson’s disease using the company’s Brainonly platform. As part of the project, Montara will design and develop an LRRK2 inhibitor drug candidate that can reach the brain and avoid the adverse effects typically associated with blocking LRRK2 in peripheral organs, such as the lungs and kidneys.
Sensors, machine learning aid in ID'ing Parkinson's-like movement disorders

2 weeks ago | parkinsonsnewstoday.com | Andrea Lobo

Integrating movement sensors and machine learning approaches may aid a correct diagnosis of movement disorders, including essential tremor and myoclonus, a study in the Netherlands suggests. Essential tremor is a progressive movement disorder marked by tremors, while myoclonus refers to brief, shock-like muscle jerks. Both can occur during voluntary movements and may resemble motor symptoms seen in Parkinson’s disease, making them challenging to distinguish in clinical practice.